Thing is, my suspicion is that it will be considered independently, because its used for a different indication. Hence the accelerated approval pathway in this particular indication for Peds Steroid Refractory Acute GVHD.
@otherperspective posted something very good about this today. Which I will repost here -
MSB to dispute FDA finding in Type A meeting, page-5
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.05 |
Change
-0.015(1.41%) |
Mkt cap ! $1.198B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.09 | $1.05 | $4.232M | 3.978M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 61694 | $1.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.06 | 45910 | 3 |
View Market Depth
| Last trade - 16.10pm 15/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.06 |
Change
-0.015 ( 0.63 %) |
||||
| Open | High | Low | Volume | ||
| $1.09 | $1.09 | $1.05 | 969435 | ||
| Last updated 15.59pm 15/05/2024 ? | |||||
| MSB (ASX) Chart |